Shares plunged as much as 5.7% on October 13 after Johnson & Johnson's quarterly results revealed a widening crack in its medical-device business, erasing billions in market value even as the company posted better-than-expected profits. The stock had been up more than 27% this year before the pullback , making the sell-off a sharp rebuke from a market that demands growth across both of J&J's pillars — not just one.
The Device Business Missed for the Second Straight Quarter
This was the second consecutive quarter that MedTech missed analyst estimates, with sales rising just 2.5% to $8.6 billion versus the $8.71 billion Wall Street expected.
The surgery segment actually shrank 0.6% year over year , while international MedTech sales were nearly flat, growing only 0.1% outside the U.S. J&J's own MedTech chief admitted performance was "below the standard we have set internally." A one-quarter miss can be forgiven; a pattern forces investors to question whether the problem is temporary or structural.
The Earnings Beat and Raised Guidance Weren't Enough to Change the Narrative
J&J reported adjusted earnings of $2.59 per share, beating consensus by $0.06, and raised its full-year sales forecast to $101.2 billion with adjusted EPS guidance lifted to $11.10. Yet adjusted EPS still fell 6.8% from a year ago , partly because of dilution from recent acquisitions. At 22 times adjusted earnings and nearly 29 times free cash flow , the stock leaves little room for any segment to underperform. The guidance raise — just six cents — was too small to offset the device disappointment.
An Orthopedics Spin-Off May Reshape the Story
J&J had been weighing options for its orthopedics unit, including reported talks with Apollo Global Management, but CFO Joseph Wolk now says he prefers a spin-off , arguing that depressed MedTech valuations mean potential buyers would use those low prices to their advantage — "not optimal for the long-term J&J shareholder." A spin-off could unlock value, but it also removes a revenue stream and shrinks the company.
Pharma Is Carrying the Load — For Now
The drug division delivered $16.8 billion in sales, up 7.9% operationally , powered by immunology blockbuster Tremfya, which surged 68% year over year. But leaning on a few mega-brands creates concentration risk. Investors will watch whether device-side weakness persists into Q4 — or whether this is the quarter that finally set a floor.